Erasca shared its third-quarter results for 2026, noting FDA Fast Track approval for its drug ERAS-0015.

Nov 12, 2026, 4:53 PM ETResultsRead the original at SEC EDGAR

Good for ERAS

Erasca has $947.8 million in cash and securities, and the FDA gave ERAS-0015 Fast Track status, supporting planned trials. The company has not yet reported new patient results, so treatment benefit remains unproven.

ERAS · Erasca, Inc.

AI read · Good for ERAS

The AI's read

That reserve gives Erasca funding for its stated trial plans, and the FDA status allows more frequent talks with the agency. These are concrete steps for its cancer programs. No new patient results are reported, so treatment benefit remains unproven.

Get alerts for ERAS

Follow Erasca, Inc. (ERAS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ERAS

Free on the App Store and Google Play, or on the web.